인터페론-alpha2b로 치료한 흑색종 환자에서 발생한 양극성 증후군 - 증 례 보 고 -

Interferon-alpha2b Induced Bipolar Syndrome in Patient with Melanoma - A Case Report -

The use of a high dose regimen of interferon (INF) has recently been demonstrated to benefit patients with malignant melanoma and the use of high dose INF for stage IIB and III melanoma was approved by Food and Drug Administration in 1995. The therapeutic benefits of INF are sometimes hampered by their severe and troublesome adverse effects including depression, mania, and cognitive impairment. The authors report a melanoma patient treated with adjuvant INF-alpha2b who developed a manic-depressive syndrome or mood instability with therapy and we reviewed literatures on mania and mixed affective syndrome associated with INF